Controversial Alzheimer’s Drug Faces Critical Test Before F.D.A. Panel

If ultimately approved, the drug, aducanumab, made by Biogen, would be the first new Alzheimer’s treatment in nearly two decades. Some evidence suggests it slows, but does not stop, cognitive decline.
New York Times
By BY PAM BELLUCK from NYT Health https://ift.tt/3jZ7hgp
November 6, 2020 at 12:00AM